OppenheimerFunds Inc. cut its position in shares of C.R. Bard, Inc. (NYSE:BCR) by 0.1% during the first quarter, Holdings Channel reports. The institutional investor owned 289,923 shares of the medical instruments supplier’s stock after selling 432 shares during the period. OppenheimerFunds Inc. owned 0.40% of C.R. Bard worth $72,058,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Cribstone Capital Management LLC acquired a new position in C.R. Bard during the first quarter worth $130,000. SRS Capital Advisors Inc. acquired a new position in C.R. Bard during the fourth quarter worth $133,000. Contravisory Investment Management Inc. raised its position in C.R. Bard by 349.2% in the first quarter. Contravisory Investment Management Inc. now owns 548 shares of the medical instruments supplier’s stock worth $136,000 after buying an additional 426 shares in the last quarter. Whittier Trust Co. raised its position in C.R. Bard by 7.7% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical instruments supplier’s stock worth $147,000 after buying an additional 42 shares in the last quarter. Finally, ClariVest Asset Management LLC acquired a new position in C.R. Bard during the first quarter worth $148,000. Institutional investors and hedge funds own 88.32% of the company’s stock.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

C.R. Bard, Inc. (NYSE:BCR) traded down 0.12% during trading on Friday, hitting $313.56. 728,015 shares of the company’s stock were exchanged. The company has a market cap of $22.71 billion, a price-to-earnings ratio of 39.91 and a beta of 0.64. The firm has a 50 day moving average price of $309.48 and a 200 day moving average price of $257.26. C.R. Bard, Inc. has a 52-week low of $203.63 and a 52-week high of $315.29.

C.R. Bard (NYSE:BCR) last posted its quarterly earnings data on Sunday, April 23rd. The medical instruments supplier reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.22. The firm had revenue of $938.80 million during the quarter, compared to analysts’ expectations of $916.15 million. C.R. Bard had a return on equity of 48.72% and a net margin of 15.70%. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the business posted $2.34 EPS. On average, equities research analysts predict that C.R. Bard, Inc. will post $11.78 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 4th. Investors of record on Monday, July 24th will be given a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date of this dividend is Thursday, July 20th. C.R. Bard’s dividend payout ratio is presently 13.21%.

WARNING: This report was reported by Financial Market News and is the sole property of of Financial Market News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.financial-market-news.com/2017/06/17/oppenheimerfunds-inc-sells-432-shares-of-c-r-bard-inc-bcr.html.

A number of research analysts recently weighed in on the stock. Cowen and Company lifted their price objective on shares of C.R. Bard from $240.00 to $317.00 and gave the company a “market perform” rating in a research note on Monday, April 24th. Zacks Investment Research raised shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price objective for the company in a report on Tuesday, June 6th. Jefferies Group LLC lifted their price objective on shares of C.R. Bard from $237.00 to $317.00 and gave the stock a “hold” rating in a report on Monday, April 24th. Wells Fargo & Company downgraded shares of C.R. Bard from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 25th. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $255.00 price objective on shares of C.R. Bard in a report on Tuesday, April 11th. Eleven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. C.R. Bard presently has a consensus rating of “Hold” and a consensus price target of $265.62.

In related news, VP Frank Lupisella, Jr. sold 3,622 shares of C.R. Bard stock in a transaction dated Monday, April 24th. The stock was sold at an average price of $304.00, for a total transaction of $1,101,088.00. Following the completion of the sale, the vice president now owns 10,139 shares in the company, valued at approximately $3,082,256. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.80% of the company’s stock.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.